Patent · US Active

Optimized antibodies that target CD19

US10626182B2 · kind B2 · utility

1Cited by

55References

27Claims

0Family size

Assignee

Xencor, Inc. · US

Inventors

Matthew Bernett · Monrovia, US
Seung Chu · Cypress, US
John Desjarlais · Pasadena, US
Sher Bahadur Karki · Pasadena, US
Gregory Alan Lazar · Los Angeles, US
Erik Weiking Pong · Temple City, US
John O. Richards · Duarte, US
Eugene Zhukovsky · West Hollywood, US

Key dates

Filing date	Sep 22, 2017
Grant date	Apr 21, 2020
Priority date	—
Expiry date	Apr 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.